Chimeric mice generated from cells reprogrammed for pluripotency (induced pluripotent stem cells, or iPS cells) show significant health problems, pointing to further challenges that must be overcome before such cells can be used in the clinic, noted iPS researcher Shinya Yamanaka said on Saturday (June 14). Speaking at the linkurl:meeting; of the linkurl:International Society for Stem Cell Research; in Philadelphia, Yamanaka presented results from his group's experiments on three types of mouse chimeras generated from mouse iPS cells so far. One type was generated from fibroblasts using a cocktail of four retrovirally delivered transcription factors, Oct-3/4, SOX2, c-Myc, and Klf4. The second type of chimera was made without the use of c-Myc, which has been implicated in causing tumors. Finally, they also generated chimeras using iPS cells derived from linkurl:liver and stomach cells.; Yamanaka reported that, not surprisingly, half of the mice generated with c-Myc developed tumors, most often in...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?